Showing posts with label Chronic. Show all posts
Showing posts with label Chronic. Show all posts

Thursday, September 26, 2013

0 The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease

Open Access


Research


The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease



Qin Wang, Yunshan Wang, Yi Zhang, Yuke Zhang and Wei Xiao










For all author emails, please log on.








Respiratory Research 2013, 14:67 doi:10.1186/1465-9921-14-67

Published: 28 June 2013





Abstract (provisional)


Background


Epithelial-mesenchymal transition (EMT) plays a crucial role in small airway fibrosis of patients with chronic obstructive pulmonary disease (COPD). Increasing evidence suggests that the urokinase plasminogen activator receptor (uPAR) is involved in the pathogenesis of COPD. Increased uPAR expression has been implicated in the promotion of EMT in numerous cancers; however the role of uPAR in EMT in small airway epithelial cells of patients with COPD remains unclear. In this study, we investigated the degree of EMT and uPAR expression in lung epithelium of COPD patients, and verified the effect of uPAR on cigarette smoke extract (CSE)-induced EMT in vitro.

Methods


The expression of EMT biomarkers and uPAR was assessed in lung epithelium specimens from non-smokers (n = 25), smokers (n = 25) and non-smokers with COPD (n = 10) and smokers with COPD (n = 18). The role of uPAR on CSE-induced EMT in human small airway epithelial cells (HSAEpiCs) was assessed by silencing uPAR expression in vitro.

Results


Markers of active EMT and uPAR expression were significantly increased in the small airway epithelium of patients with COPD compared with controls. We also observed a significant correlation between uPAR and vimentin expression in the small airway epithelium. In vitro, CSE-induced EMT in HSAEpiCs was associated with high expression of uPAR, and targeted silencing of uPAR using shRNA inhibited CSE-induced EMT. Finally, we demonstrate that the PI3K/Akt signaling pathway is required for uPAR-mediated EMT in HSAEpiCs.

Conclusions


A uPAR-dependent signaling pathway is required for CSE-induced EMT, which contributes to small airway fibrosis in COPD. We propose that increased uPAR expression in the small airway epithelium of patients with COPD participates in an active EMT process.






The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.



0 Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology








The Journal of Allergy and Clinical Immunology
Volume 131, Issue 6 , Pages 1479-1490, June 2013



Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology





Received 31 October 2012; received in revised form 11 February 2013; accepted 14 February 2013. published online 15 April 2013.



Chronic rhinosinusitis (CRS) is a complex disease consisting of several disease variants with different underlying pathophysiologies. Limited knowledge of the mechanisms of these disease subgroups is possibly the greatest obstacle in understanding the causes of CRS and improving treatment. It is generally agreed that there are clinically relevant CRS phenotypes defined by an observable characteristic or trait, such as the presence or absence of nasal polyps. Defining the phenotype of the patient is useful in making therapeutic decisions. However, clinical phenotypes do not provide full insight into all underlying cellular and molecular pathophysiologic mechanisms of CRS. Recognition of the heterogeneity of CRS has promoted the concept that CRS consists of multiple groups of biological subtypes, or “endotypes,” which are defined by distinct pathophysiologic mechanisms that might be identified by corresponding biomarkers. Different CRS endotypes can be characterized by differences in responsiveness to different treatments, including topical intranasal corticosteroids and biological agents, such as anti–IL-5 and anti-IgE mAb, and can be based on different biomarkers that are linked to underlying mechanisms. CRS has been regarded as a single disease entity in clinical and genetic studies in the past, which can explain the failure to identify consistent genetic and environmental correlations. In addition, better identification of endotypes might permit individualization of therapy that can be targeted against the pathophysiologic processes of a patient’s endotype, with potential for more effective treatment and better patient outcomes.



 



 Disclosure of potential conflict of interest: C. A. Akdis receives research support from Novartis, PREDICTA, the Swiss National Science Foundation, MeDALL, the Global Allergy and Asthma European Network, and the Christine Kühne-Center for Allergy Research and Education; has consulted for Actellion, Aventis, Stallergenes, and Allergopharma; is president of the European Academy of Allergy and Clinical Immunology; is a fellow and interest group member of the American Academy of Allergy, Asthma & Immunology (AAAAI); is a former committee member of the Global Allergy and Asthma European Network; and is the director of the Christine Kühne-Center for Allergy Research and Education. C. Bachert has received research support from Novartis and GlaxoSmithKline. M. S. Dykewicz has consultant arrangements with Boehringer Ingelheim, Ista, and Merck. R. M. Naclerio has received travel support from AAAAI; has board memberships with Merck, TEVA, and Sunovion; has received grants from TEVA, Johnson & Johnson, and Kalypsis; and has received payment for lectures from TEVA and Sunovion. R. P. Schleimer has consultant arrangements with Intersect ENT, GlaxoSmithKline, Allakos, and Aurasense; has received research support from the National Institutes of Health; and has received stock/stock options from Allakos. D. Ledford has received travel support from AAAAI; has consultant arrangements with Genentech; and has received payment for lectures from Meda and Genentech. The rest of the authors declare that they have no relevant conflicts of interest.

PII: S0091-6749(13)00367-9

doi:10.1016/j.jaci.2013.02.036





The Journal of Allergy and Clinical Immunology
Volume 131, Issue 6 , Pages 1479-1490, June 2013



Sunday, September 15, 2013

0 A proposed model to study immunologic changes during chronic rhinosinusitis exacerbations



Logo of rhinol

American Journal of Rhinology & Allergy










Am J Rhinol Allergy. 2013 Mar-Apr; 27(2): 98–101.

Published online 2013 January 30. doi:  10.2500/ajra.2013.27.3850




PMCID: PMC3610944





A proposed model to study immunologic changes during chronic rhinosinusitis exacerbations: Data from a pilot study



Matthew A. Rank, M.D.,corresponding author1 John B. Hagan, M.D.,2 Shefali A. Samant, M.D.,2 and Hirohito Kita, M.D.2







Abstract




Background:


One way to gain insight into the pathophysiology of chronic rhinosinusitis (CRS) is to study the immunologic changes that occur with exacerbation. This study describes the immunologic changes during CRS exacerbation



Methods:


We performed a prospective study to investigate the immunologic changes seen during exacerbation of CRS with nasal polyposis. We recruited adult subjects who met clinical criteria for CRS with sinus CT scan within the past 5 years with Lund-Mackay score of >5 and nasal polyps. Subjects underwent a baseline visit with collection of nasal secretion and nasal wash. With acute worsening of symptoms, subjects underwent 6 near-consecutive-day collections and one follow-up collection 2 weeks later. IL-6, IL-33, eosinophil major basic protein (MBP), eosinophil-derived neurotoxin (EDN), myeloperoxidase (MPO), and uric acid were measured on the nasal samples from each visit.



Results:


A total of 10 subjects were recruited and 9 had acute worsening of CRS during the study period. Eight of the nine subjects were women and ages ranged from 26 to 56 years. At baseline, most inflammatory parameters were low and eight of the nine subjects were on intranasal corticosteroids. Compared with baseline measurements, IL-6, MBP, MPO, EDN, and uric acid were significantly elevated during CRS exacerbation. Levels of IL-6 and MBP (r = 0.47) levels as well as IL-6 and MPO (r = 0.75) were both significantly correlated (p < 0.01).



Conclusion:


Prospective study of CRS exacerbations is feasible and provides insights into the immunologic mechanisms of CRS.


Formats:








Hypnosis and Chronic Pain


Pain’s Many Idiosyncrasies
Even as researchers make strides in understanding and treating pain, new discoveries raise many more questions. These recent findings reveal the deep connections between pain and many essential physical and mental processes.



  • Patients with chronic back pain tend to be impaired at emotional learning but have increased sensitivity to taste.

  • Chronic pain shrinks the brain, up to 11 percent in some cases.

  • Those with chronic pain can learn to control their perception of pain by imagining pleasant scenarios or believing a particular stimulus to be harmless.

  • Memory of a pain can cause that pain to persist for life, even after the initial injury has healed.

  • Chronic pain sufferers can learn to associate a place with their pain. Returning to this space can reinforce the negative association.



Labels: , , ,